{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:59:36Z","timestamp":1791237576476,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-07622-x","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T12:41:21Z","timestamp":1739018481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism"],"prefix":"10.1038","volume":"8","author":[{"given":"Lijun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8843-6305","authenticated-orcid":false,"given":"Ruili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2335-2346","authenticated-orcid":false,"given":"Qiongzi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-876X","authenticated-orcid":false,"given":"Xiangpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"7622_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"R. L Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"7622_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"J. D Yang","year":"2019","unstructured":"Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589\u2013604 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"7622_CR3","doi-asserted-by":"crossref","unstructured":"Simile, M. M. et al. Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials. Medicina 55, 42 (2019).","DOI":"10.3390\/medicina55020042"},{"key":"7622_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","volume":"16","author":"J Bruix","year":"2019","unstructured":"Bruix, J., da Fonseca, L. G. & Reig, M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 16, 617\u2013630 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"7622_CR5","doi-asserted-by":"publisher","DOI":"10.2217\/hep-2018-0002","volume":"5","author":"R Kumari","year":"2018","unstructured":"Kumari, R., Sahu, M. K., Tripathy, A., Uthansingh, K. & Behera, M. Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat. Oncol. 5, HEP08 (2018).","journal-title":"Hepat. Oncol."},{"key":"7622_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/apt.15573","volume":"51","author":"S Bangaru","year":"2020","unstructured":"Bangaru, S., Marrero, J. A. & Singal, A. G. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharm. Ther. 51, 78\u201389 (2020).","journal-title":"Aliment Pharm. Ther."},{"key":"7622_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","volume":"16","author":"A. X Zhu","year":"2015","unstructured":"Zhu, A. X. et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 16, 859\u2013870 (2015).","journal-title":"Lancet Oncol."},{"key":"7622_CR8","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"A. B El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"7622_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jceh.2019.01.004","volume":"9","author":"A Jindal","year":"2019","unstructured":"Jindal, A., Thadi, A. & Shailubhai, K. Hepatocellular carcinoma: etiology and current and future drugs. J. Clin. Exp. Hepatol. 9, 221\u2013232 (2019).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"7622_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-021-00594-4","volume":"6","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1beta in hepatocellular carcinoma. Signal Transduct. Target Ther. 6, 190 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"7622_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0159-1","volume":"50","author":"C Mendez-Blanco","year":"2018","unstructured":"Mendez-Blanco, C., Fondevila, F., Garcia-Palomo, A., Gonzalez-Gallego, J. & Mauriz, J. L. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp. Mol. Med. 50, 1\u20139 (2018).","journal-title":"Exp. Mol. Med."},{"key":"7622_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/19768354.2023.2234986","volume":"27","author":"H Jeong","year":"2023","unstructured":"Jeong, H., Lee, B., Han, S. J. & Sohn, D. H. Glucose metabolic reprogramming in autoimmune diseases. Anim. Cells Syst.27, 149\u2013158 (2023).","journal-title":"Anim. Cells Syst."},{"key":"7622_CR13","doi-asserted-by":"crossref","unstructured":"Faubert, B., Solmonson, A. & DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science 368, eaaw5473 (2020).","DOI":"10.1126\/science.aaw5473"},{"key":"7622_CR14","doi-asserted-by":"crossref","unstructured":"Bao, M. H. R. & Wong, C. C. L. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells 10, 1715 (2021).","DOI":"10.3390\/cells10071715"},{"key":"7622_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/metabo5040571","volume":"5","author":"M Rahman","year":"2015","unstructured":"Rahman, M. & Hasan, M. R. Cancer metabolism and drug resistance. Metabolites 5, 571\u2013600 (2015).","journal-title":"Metabolites"},{"key":"7622_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.bbrc.2014.07.114","volume":"451","author":"D Kikuchi","year":"2014","unstructured":"Kikuchi, D., Minamishima, Y. A. & Nakayama, K. Prolyl-hydroxylase PHD3 interacts with pyruvate dehydrogenase (PDH)-E1beta and regulates the cellular PDH activity. Biochem. Biophys. Res. Commun. 451, 288\u2013294 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"7622_CR17","doi-asserted-by":"crossref","unstructured":"Larrieu, C. M. et al. Refining the role of pyruvate dehydrogenase kinases in glioblastoma development. Cancers 14, 3769 (2022).","DOI":"10.3390\/cancers14153769"},{"key":"7622_CR18","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1158\/0008-5472.CAN-17-1751","volume":"78","author":"R Yonashiro","year":"2018","unstructured":"Yonashiro, R., Eguchi, K., Wake, M., Takeda, N. & Nakayama, K. Pyruvate dehydrogenase PDH-E1beta controls tumor progression by altering the metabolic status of cancer cells. Cancer Res. 78, 1592\u20131603 (2018).","journal-title":"Cancer Res."},{"key":"7622_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40170-021-00275-4","volume":"9","author":"N. P Echeverri Ruiz","year":"2021","unstructured":"Echeverri Ruiz, N. P. et al. Dynamic regulation of mitochondrial pyruvate metabolism is necessary for orthotopic pancreatic tumor growth. Cancer Metab. 9, 39 (2021).","journal-title":"Cancer Metab."},{"key":"7622_CR20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3109\/13880209.2011.604089","volume":"50","author":"S Sannigrahi","year":"2012","unstructured":"Sannigrahi, S., Mazumder, U. K., Pal, D. & Mishra, S. L. Terpenoids of methanol extract of Clerodendrum infortunatum exhibit anticancer activity against Ehrlich\u2019s ascites carcinoma (EAC) in mice,. Pharm. Biol. 50, 304\u2013309 (2012).","journal-title":"Pharm. Biol."},{"key":"7622_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/15287390590900750","volume":"68","author":"S Chae","year":"2005","unstructured":"Chae, S. et al. Antioxidant activity of isoacteoside from Clerodendron trichotomum. J. Toxicol. Environ. Health A 68, 389\u2013400 (2005).","journal-title":"J. Toxicol. Environ. Health A"},{"key":"7622_CR22","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1111\/bph.13912","volume":"174","author":"H Gao","year":"2017","unstructured":"Gao, H. et al. Isoacteoside, a dihydroxyphenylethyl glycoside, exhibits anti-inflammatory effects through blocking toll-like receptor 4 dimerization. Br. J. Pharm. 174, 2880\u20132896 (2017).","journal-title":"Br. J. Pharm."},{"key":"7622_CR23","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1080\/09168451.2019.1637243","volume":"83","author":"S. L Ji","year":"2019","unstructured":"Ji, S. L. et al. Antioxidant activity of phenylethanoid glycosides on glutamate-induced neurotoxicity. Biosci. Biotechnol. Biochem. 83, 2016\u20132026 (2019).","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"7622_CR24","first-page":"285","volume":"24","author":"X Yang","year":"2019","unstructured":"Yang, X., Guo, F., Peng, Q., Liu, Y. & Yang, B. Suppression of in vitro and in vivo human ovarian cancer growth by isoacteoside is mediated via sub-G1 cell cycle arrest, ROS generation, and modulation of AKT\/PI3K\/m-TOR signalling pathway. J. BUON 24, 285\u2013290 (2019).","journal-title":"J. BUON"},{"key":"7622_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.trecan.2018.11.003","volume":"5","author":"Z Wang","year":"2019","unstructured":"Wang, Z. & Dong, C. Gluconeogenesis in cancer: function and regulation of PEPCK, FBPase, and G6Pase. Trends Cancer 5, 30\u201345 (2019).","journal-title":"Trends Cancer"},{"key":"7622_CR26","doi-asserted-by":"crossref","unstructured":"Chakraborty, E. & Sarkar, D. Emerging therapies for hepatocellular carcinoma (HCC). Cancers 14, 2798 (2022).","DOI":"10.3390\/cancers14112798"},{"key":"7622_CR27","unstructured":"Asafo-Agyei, K. O. & Samant, H. Hepatocellular carcinoma. StatPearls, Treasure Island (FL) ineligible companies. Disclosure: Hrishikesh Samant declares no relevant financial relationships with ineligible companies (2023)."},{"key":"7622_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A. L Cheng","year":"2009","unstructured":"Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"7622_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang, A., Yang, X. R., Chung, W. Y., Dennison, A. R. & Zhou, J. Targeted therapy for hepatocellular carcinoma. Signal Transduct. Target Ther. 5, 146 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"7622_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4149\/neo_2020_200813N858","volume":"68","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. LncRNA MEG3 promotes endoplasmic reticulum stress and suppresses proliferation and invasion of colorectal carcinoma cells through the MEG3\/miR-103a-3p\/PDHB ceRNA pathway. Neoplasma 68, 362\u2013374 (2021).","journal-title":"Neoplasma"},{"key":"7622_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1042\/BST0340217","volume":"34","author":"M. S Patel","year":"2006","unstructured":"Patel, M. S. & Korotchkina, L. G. Regulation of the pyruvate dehydrogenase complex. Biochem. Soc. Trans. 34, 217\u2013222 (2006).","journal-title":"Biochem. Soc. Trans."},{"key":"7622_CR32","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1074\/jbc.RA118.005200","volume":"294","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Metabolic and oncogenic adaptations to pyruvate dehydrogenase inactivation in fibroblasts. J. Biol. Chem. 294, 5466\u20135486 (2019).","journal-title":"J. Biol. Chem."},{"key":"7622_CR33","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s00018-013-1539-2","volume":"71","author":"L. R Gray","year":"2014","unstructured":"Gray, L. R., Tompkins, S. C. & Taylor, E. B. Regulation of pyruvate metabolism and human disease. Cell Mol. Life Sci. 71, 2577\u20132604 (2014).","journal-title":"Cell Mol. Life Sci."},{"key":"7622_CR34","doi-asserted-by":"crossref","unstructured":"Stacpoole, P. W. Therapeutic targeting of the pyruvate dehydrogenase complex\/pyruvate dehydrogenase kinase (PDC\/PDK) axis in cancer. J. Natl Cancer Inst. 109, 11 (2017).","DOI":"10.1093\/jnci\/djx071"},{"key":"7622_CR35","doi-asserted-by":"crossref","unstructured":"Shiao, Y. J., Su, M. H., Lin, H. C. & Wu, C. R. Acteoside and isoacteoside protect amyloid beta peptide induced cytotoxicity, cognitive deficit and neurochemical disturbances in vitro and in vivo. Int. J. Mol. Sci. 18, (2017).","DOI":"10.3390\/ijms18040895"},{"key":"7622_CR36","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/hep.26720","volume":"59","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 59, 1850\u20131863 (2014).","journal-title":"Hepatology"},{"key":"7622_CR37","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013W514 (2020).","journal-title":"Nucleic Acids Res."},{"key":"7622_CR38","doi-asserted-by":"crossref","unstructured":"The TCGA legacy. Cell 173, 281\u2013282 (2018).","DOI":"10.1016\/j.cell.2018.03.049"},{"key":"7622_CR39","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 47, W556\u2013W560 (2019).","journal-title":"Nucleic Acids Res"},{"key":"7622_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"D. S Chandrashekar","year":"2022","unstructured":"Chandrashekar, D. S. et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25, 18\u201327 (2022).","journal-title":"Neoplasia"},{"key":"7622_CR41","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk, D. et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 49, D605\u2013D612 (2021).","journal-title":"Nucleic Acids Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07622-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T12:41:30Z","timestamp":1739018490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07622-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7622"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-07622-x","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal care and experimental studies were performed according to the guidelines and approval of the Ethics Committee of Xinxiang Medical University (Approval Number: XYLL-20200653; Date: 2020.08.01). This study included 30 patients was conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent. Patient information was completely anonymized. The study protocol was approved by the Ethics Committee of Xinxiang Medical University (Approval Number: XYLL-20200653; Date: 2020.08.01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"205"}}